Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer

Breast Cancer Research and Treatment

Volumn 119, Issue 1, 2010, Pages 111-118

  Khan, Qamar J ^a   Reddy, Pavan S ^b   Kimler, Bruce F ^a   Sharma, Priyanka ^a   Baxa, Susan E ^a   O'Dea, Anne P ^a   Klemp, Jennifer R ^a   Fabian, Carol J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Cancer Centers of Kansas   (United States)

Author keywords

Aromatase inhibitors; Arthralgias; Breast cancer; Endocrine therapy; Joint pain; Letrozole; Vitamin D; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; LETROZOLE; PLACEBO; UNCLASSIFIED DRUG; VIACTIV; VITAMIN;

ADJUVANT THERAPY; ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NEPHROLITHIASIS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DIETARY SUPPLEMENTS; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TREATMENT OUTCOME; TRIAZOLES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 72449171943     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0495-x     Document Type: Article

References (30)

1. M Baum AU Budzar J Cuzick, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D 12090977 (Pubitemid 34694019)
2. A Howell J Cuzick M Baum, et al. 2005 Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 10.1016/S0140-6736(05)74803-0 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 15639680
3. AS Coates A Keshaviah B Thürlimann, et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492 10.1200/JCO.2006.08.8617 1:CAS:528:DC%2BD2sXivF2mt7Y%3D 17200148 (Pubitemid 350002953)
4. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer New Engl J Med 350 1081 1092 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D 15014181 (Pubitemid 38298988)
5. RC Coombes LS Kilburn CF Snowdon, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomized controlled trial Lancet 369 559 570 10.1016/S0140-6736(07)60200-1 1:CAS:528:DC%2BD2sXhvVGgsro%3D 17307102 (Pubitemid 46251559)
6. KD Crew H Greenlee J Capodice, et al. 2007 Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer J Clin Oncol 25 3877 3883 10.1200/JCO.2007.10.7573 17761973 (Pubitemid 47477264)
7. AH Partridge A LaFountain E Mayer, et al. 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556 562 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D 18180462 (Pubitemid 351264348)
8. S Dent T DeValentin L Vandermeer, et al. 2006 Long-term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center Breast Cancer Res Treat 100 suppl 1 S190 (abstr 4057)
9. L Morales P Neven D Timmerman, et al. 2004 Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer Anti-Cancer Drugs 15 753 760 10.1097/00001813-200409000-00003 1:CAS:528:DC%2BD2cXntVejtLo%3D 15494636 (Pubitemid 39281298)
10. MF Holick 2006 High prevalence of vitamin D inadequacy and implications for health Mayo Clin Proc 1 353 373 10.4065/81.3.353
11. MF Holick 2007 Vitamin D deficiency N Engl J Med 357 266 281 10.1056/NEJMra070553 1:CAS:528:DC%2BD2sXotVejsbc%3D 17634462 (Pubitemid 47080391)
12. HA Bischoff-Ferrari T Dietrich EJ Orav, et al. 2004 Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged ≥60 y Am J Clin Nutr 80 752 758 1:CAS:528:DC%2BD2cXnsVWhsrg%3D 15321818
13. Taylor M, Rastelli A, Civitelli R et al. (2004) Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology. 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX (abstract 3072)
14. GA Plotnikoff JM Quigley 2003 Prevalence of severe hypovitaminosis D in patients with persistent nonspecific musculoskeletal pain Mayo Clin Proc 78 1463 1470 10.4065/78.12.1463 14661675
15. MK Thomas DM Lloyd-Jones RI Thadhani, et al. 1998 Hypovitaminosis D in medical inpatients N Engl J Med 338 777 783 10.1056/NEJM199803193381201 1:STN:280:DyaK1c7lvVSgsw%3D%3D 9504937 (Pubitemid 28135983)
16. A Malabanan IE Veronikis MF Holick 1998 Redefining vitamin D insufficiency [letter] Lancet 351 805 806 10.1016/S0140-6736(05)78933-9 1:STN:280:DyaK1c7nvVOrsA%3D%3D 9519960
17. DA Hanley KS Davison 2005 Vitamin D insufficiency in North America J Nutr 135 332 337 1:CAS:528:DC%2BD2MXhsVKju70%3D 15671237
18. JR Buchanan R Santen S Cauffman A Cavaliere RB Greer LM Demers 1986 The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D Calcif Tissue Int 39 139 144 10.1007/BF02555109 1:CAS:528:DyaL28XlvVChs74%3D 3093024
19. F Wolfe K Michaud T Pincus 2004 Development and validation of health assessment questionnaire II: a revised version of health assessment questionnaire Arthritis Rheum 50 3296 3305 10.1002/art.20549 15476213 (Pubitemid 39372007)
20. TR Mendoza XS Wang CS Cleeland M Morrissey BA Johnson JK Wendt SL Huber 1999 The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory Cancer 85 1186 1196 10.1002/(SICI)1097-0142(19990301)85: 5<1186::AID-CNCR24>3.0.CO;2-N 1:STN:280:DyaK1M7ptVahtA%3D%3D 10091805 (Pubitemid 29115600)
21. JR Hilditch J Lewis A Peter B van Maris 1996 A menopause-specific quality of life questionnaire: development and psychometric properties Maturitas 6 161 175
22. AM Brodie VC Njar 1996 Aromatase inhibitors and breast cancer Semin Oncol 23 4 Suppl 9 10 20 1:CAS:528:DyaK28XmsFOktLo%3D 8824460
23. PE Lønning J Geisler LE Krag, et al. 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasmalipids in patients with surgically resected early breast cancer J Clin Oncol 23 4847 4849 10.1200/JCO.2005.03.903 (Pubitemid 46223987)
24. MC Chapuy ME Arlot F Duboeuf, et al. 1992 Vitamin D3 and calcium to prevent hip fractures in elderly women N Engl J Med 327 1637 1642 1:STN:280:DyaK3s%2FmtlSrug%3D%3D 1331788
25. MF Holick ES Siris N Binkley, et al. 2005 Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy J Clin Endocrinol Metab 90 3215 3224 10.1210/jc.2004-2364 1:CAS:528:DC%2BD2MXkvFClsLo%3D 15797954 (Pubitemid 41014278)
26. J Lester R Coleman 2005 Bone loss and the aromatase inhibitors Br J Cancer 93 S16 S22 10.1038/sj.bjc.6602691 1:CAS:528:DC%2BD2MXns1Wrt70%3D 16100521 (Pubitemid 44324675)
27. P Lønning J Geisler LE Krag, et al. 2006 Vitamin D deficiency: a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors J Clin Oncol 24 18s 10.1200/JCO.2006.06.1143 (abstr 554)
28. KD Crew E Shane S Cremers DJ McMahon D Irani DL Hershman 2009 High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy J Clin Oncol 27 2151 2156 10.1200/JCO.2008.19.6162 1:CAS:528:DC%2BD1MXlvFOgsrg%3D 19349547
29. RP Heaney 2003 Long-latency deficiency disease: insights from calcium and vitamin D Am J Clin Nutr 78 912 919 1:CAS:528:DC%2BD3sXoslCjsbo%3D 14594776
30. GA Wells P Tugwell GR Kraag PR Baker J Groh DA Redelmeier 1993 Minimum important difference between patients with rheumatoid arthritis: the patient's perspective J Rheumatol 20 557 560 1:STN:280:DyaK3s3ktVCmtA%3D%3D 8478873